Laurus Labs’ API plant in Vizag gets EIR from U.S. FDA 


File photo used for representational purpose only.

File photo used for representational purpose only.
| Photo Credit: The Hindu

An active pharmaceutical ingredients manufacturing facility of Laurus Labs in Visakhapatnam that received an observation post an inspection by United States Food and Drug Administration earlier this year has been issued establishment inspection report by the regulator.

The company has received the EIR, the drugmaker said in a filing on Tuesday (April 16, 2025). The U.S. FDA had inspected the API manufacturing facility Unit–4 in Atchutapuram, Anakapalli district from January 27-31 and issued a Form 483 with one observation.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *